Anti-Cancer Drugs — Part 1

Correct Answer

C — Vinca alkaloid

Rationale

Vincristine is classified as a vinca alkaloid. Vinca alkaloids are plant-derived agents that bind to the beta-tubulin subunit at the vinca domain and suppress microtubule dynamic instability at plus ends, ultimately causing mitotic arrest and apoptosis. The vinca alkaloid class includes vincristine, vinblastine, and vinorelbine. Taxanes (paclitaxel, docetaxel) stabilize microtubules by a different mechanism at a different binding site. Epipodophyllotoxins (etoposide) inhibit topoisomerase II. Antitumor antibiotics (bleomycin, doxorubicin) have distinct mechanisms of deoxyribonucleic acid damage.

Correct Answer

A — Taxane

Rationale

Paclitaxel is classified as a taxane. Taxanes bind to the beta-tubulin subunit on the interior of the microtubule lumen, stabilizing the polymer by suppressing dynamic instability and preventing tubulin depolymerization, which locks the mitotic spindle in a non-functional state and triggers apoptosis. The taxane class includes paclitaxel, docetaxel, cabazitaxel, and nab-paclitaxel. Vinca alkaloids (vincristine, vinblastine) act at a different tubulin domain and by the opposing mechanism of microtubule destabilization. Epipodophyllotoxins (etoposide) and anthracyclines (doxorubicin) inhibit topoisomerase II through unrelated mechanisms.

Correct Answer

B — Epothilone B analog

Rationale

Ixabepilone is classified as an epothilone B analog. Epothilones are a distinct class of microtubule-stabilizing agents that bind to the same beta-tubulin binding site as taxanes on the interior of the microtubule lumen but have a different chemical structure. Ixabepilone was developed as a semisynthetic derivative of epothilone B to retain activity against tumors that have developed taxane resistance through P-glycoprotein overexpression or beta-III tubulin isotype upregulation. Although ixabepilone shares the microtubule-stabilizing mechanism with taxanes, it is classified as an epothilone, not a taxane. Vinca alkaloids and camptothecin derivatives are mechanistically unrelated classes.

Correct Answer

D — Albumin-bound paclitaxel nanoparticle formulation

Rationale

Nab-paclitaxel is classified as an albumin-bound paclitaxel nanoparticle formulation. In this formulation, paclitaxel is bound noncovalently to human serum albumin to form 130-nanometer nanoparticles, eliminating the need for the Cremophor EL vehicle required by conventional paclitaxel. Conventional paclitaxel uses Cremophor EL (polyoxyethylated castor oil) as its solubilizing vehicle. Docetaxel uses polysorbate 80 as its vehicle. No approved liposomal taxane formulation with polyethylene glycol coating is in standard clinical use. Nab-paclitaxel requires neither the three-drug hypersensitivity premedication protocol nor polyvinyl chloride-free infusion tubing because Cremophor EL is absent.

Correct Answer

A — Polysorbate 80

Rationale

Docetaxel is formulated in polysorbate 80 for intravenous administration. This distinguishes it from conventional paclitaxel, which is solubilized in Cremophor EL (polyoxyethylated castor oil). Polysorbate 80 produces a different vehicle-related toxicity profile than Cremophor EL: rather than the acute anaphylactoid hypersensitivity reaction associated with Cremophor EL, docetaxel causes a cumulative fluid retention syndrome (edema, pleural effusions, ascites) attenuated by dexamethasone premedication. Human serum albumin is the carrier in nab-paclitaxel. Polyethylene glycol-coated liposomes are used in pegylated liposomal doxorubicin, not in docetaxel.

Correct Answer

C — Vinblastine

Rationale

Vinblastine is the vinca alkaloid component of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), the standard chemotherapy regimen for Hodgkin lymphoma. Vinblastine differs from vincristine in that its dose-limiting toxicity is myelosuppression rather than peripheral neuropathy, making it more suitable for use alongside other agents in this regimen. Vincristine is used in different lymphoma regimens such as CHOP and MOPP. Paclitaxel is a taxane, not a vinca alkaloid, and is not part of ABVD. Dacarbazine is an alkylating triazene — the D in ABVD — not a vinca alkaloid.

Correct Answer

B — Vinca alkaloids suppress dynamic instability by binding to tubulin at plus ends, preventing efficient addition or loss of subunits; taxanes stabilize the microtubule polymer by binding to the interior of the lumen, suppressing depolymerization

Rationale

Vinca alkaloids and taxanes both disrupt dynamic instability — the rapid switching between polymerization and depolymerization that is essential for mitotic spindle function — but by opposite mechanisms. Vinca alkaloids bind to the vinca domain on beta-tubulin at microtubule plus ends, suppressing the kinetics of tubulin dimer addition and loss and thereby kinetically stabilizing the dynamic instability state with malformed or absent spindles; at higher concentrations they cause depolymerization. Taxanes bind to a distinct site on the interior of the microtubule lumen on the beta-tubulin subunit, stabilizing the assembled polymer by reducing the off-rate of tubulin dimers and suppressing dynamic instability from within the polymer. Both mechanisms ultimately prevent the kinetochore attachment and chromatid separation required for anaphase, triggering sustained spindle assembly checkpoint activation and apoptosis. The two drug classes bind completely different sites on beta-tubulin and produce their effects through different physical interactions with the polymer.

Correct Answer

D — Vincristine binds preferentially to axonal microtubules in peripheral neurons, impairing slow axonal transport of structural proteins and organelles in a length-dependent pattern; the doses that produce neurotoxicity are below the threshold required for myelosuppression

Rationale

Vincristine binds to axonal microtubules in peripheral sensory and motor neurons, impairing the microtubule-dependent slow axonal transport of structural proteins, organelles, and vesicles from the cell body to the axon terminal. Because axonal transport is length-dependent — longer axons require more transport capacity — the longest peripheral nerves are affected first, producing the characteristic distal-to-proximal progression of symptoms. The ankle jerk reflex, mediated by the longest sensory fibers, disappears before symptoms appear in the hands. At the doses used clinically, this axonal toxicity occurs at vincristine exposures that are insufficient to meaningfully suppress hematopoietic progenitor cell division, explaining why vincristine causes virtually no myelosuppression while producing significant neuropathy. The mechanism is direct axonal microtubule binding and impaired transport, not P-glycoprotein efflux, metabolite formation in Schwann cells, or lipophilic myelin accumulation.

Correct Answer

A — Voriconazole inhibits cytochrome P450 3A4, the primary enzyme responsible for vincristine hepatic metabolism, reducing vincristine clearance and raising plasma and tissue concentrations that increase axonal microtubule binding and neuropathy severity

Rationale

Vincristine is metabolized predominantly by hepatic cytochrome P450 3A4. Voriconazole, an azole antifungal, is a potent inhibitor of cytochrome P450 3A4. When voriconazole is co-administered with vincristine, it impairs vincristine's hepatic clearance, prolonging its plasma half-life and increasing systemic exposure. Higher vincristine plasma concentrations result in greater accumulation in peripheral axons, increasing binding to axonal microtubules and worsening neuropathy. This interaction is clinically well-documented and can cause severe and even life-threatening neurotoxicity. Voriconazole does not displace vincristine from protein binding sites in a clinically meaningful way, is not a tubulin-binding agent, and does not induce P-glycoprotein — its effect is purely pharmacokinetic through cytochrome P450 3A4 inhibition.

Correct Answer

C — Vincristine disrupts microtubule-dependent axonal transport in the hypothalamic-neurohypophyseal system, causing dysregulated antidiuretic hormone secretion independent of plasma osmolality, producing the syndrome of inappropriate antidiuretic hormone secretion

Rationale

The laboratory pattern of hyponatremia with inappropriately concentrated urine and euvolemia is the hallmark of the syndrome of inappropriate antidiuretic hormone secretion. Vincristine can cause this syndrome by disrupting microtubule-dependent axonal transport in neurons of the hypothalamic-neurohypophyseal axis — the system responsible for synthesizing antidiuretic hormone in hypothalamic nuclei and releasing it from the posterior pituitary. This transport disruption causes antidiuretic hormone to be secreted into the bloodstream independent of plasma osmolality and volume status, the defining abnormality of the syndrome. The result is free water retention with concentrated urine, dilutional hyponatremia, and euvolemia. Vincristine does not cause nephrotoxicity that impairs loop of Henle diluting capacity, does not stimulate aldosterone through adrenal microtubule disruption, and does not directly inhibit aquaporin-2 channels.

Correct Answer

B — Cremophor EL, the vehicle used to solubilize conventional paclitaxel, directly activates complement and stimulates mast cell degranulation independent of immunoglobulin E, producing an anaphylactoid reaction prevented by pretreatment with dexamethasone, diphenhydramine, and an H2 receptor antagonist

Rationale

Conventional paclitaxel is highly hydrophobic and requires solubilization in Cremophor EL (polyoxyethylated castor oil). Cremophor EL is itself a potent cause of non-immunoglobulin E-mediated hypersensitivity reactions, occurring in approximately 10 to 40% of patients without premedication. The mechanism involves direct complement activation and mast cell degranulation that does not require prior sensitization — therefore this reaction can occur on the very first infusion and does not represent true immunoglobulin E-mediated anaphylaxis. Standard premedication with dexamethasone 20 mg, diphenhydramine 50 mg intravenously, and an H2 receptor antagonist 30 minutes before infusion reduces the incidence of severe reactions to approximately 1 to 2%, allowing the majority of patients to receive subsequent cycles safely. The reaction is not caused by paclitaxel metabolites and is not an immunoglobulin E-mediated process requiring desensitization.

Correct Answer

D — Cabazitaxel has low affinity for P-glycoprotein; P-glycoprotein cannot efficiently efflux it, so it accumulates to cytotoxic concentrations even in cells that actively pump out docetaxel

Rationale

P-glycoprotein is an efflux transporter that recognizes and pumps certain drugs out of cells. Docetaxel and paclitaxel are both P-glycoprotein substrates, so tumor cells that overexpress P-glycoprotein can actively remove these drugs before they reach cytotoxic concentrations — a major mechanism of acquired taxane resistance. Cabazitaxel was developed in part because it has low affinity for P-glycoprotein. Cells that overexpress P-glycoprotein and efflux docetaxel efficiently cannot do the same to cabazitaxel, which therefore accumulates inside the cell and retains its microtubule-stabilizing cytotoxic effect. Cabazitaxel is not a prodrug, does not enter through an alternative transporter, and binds the same site on tubulin as other taxanes — the resistance evasion is entirely due to its low P-glycoprotein affinity.

Correct Answer

A — Docetaxel causes a cumulative fluid retention syndrome through its polysorbate 80 vehicle; dexamethasone 8 mg twice daily for 3 days beginning the day before each cycle substantially reduces the incidence and severity of edema, pleural effusions, and ascites

Rationale

Docetaxel causes a characteristic cumulative fluid retention syndrome, manifesting as peripheral edema, pleural effusions, and ascites that worsen with each additional cycle. This toxicity is associated with the polysorbate 80 vehicle and the docetaxel molecule and is substantially attenuated by corticosteroid premedication. The standard regimen is dexamethasone 8 mg orally twice daily for 3 days, beginning the day before each docetaxel infusion; this regimen also reduces the incidence of hypersensitivity reactions to docetaxel. Without premedication, severe fluid retention occurs in the majority of patients at cumulative docetaxel doses above 400 mg per square meter. The mechanism of fluid retention is not fully characterized but involves increased capillary permeability rather than nephrotoxicity or lymphatic impairment. Bevacizumab is not used for docetaxel fluid retention prophylaxis.

Correct Answer

C — Vinca alkaloids must never be prepared in syringes because a syringe is indistinguishable from an intrathecal preparation at the bedside; intrathecal vincristine causes a uniformly fatal ascending myeloencephalopathy for which there is no effective treatment

Rationale

Intrathecal administration of a vinca alkaloid is one of the most catastrophic medication errors in oncology. The clinical consequence is a uniformly fatal ascending myeloencephalopathy: severe radicular pain develops within hours, followed by ascending motor weakness, loss of sphincter control, progressive paralysis, brainstem involvement, respiratory failure, and death over 24 to 72 hours. There is no established effective treatment. To prevent this error, vinca alkaloids must be dispensed only in minibags — never in syringes — because a syringe is the standard container for intrathecal chemotherapy and cannot be reliably distinguished from an intrathecal preparation at the point of care. Additional mandatory safeguards include prominent warning labels on every container, an outer overpacking bag with the same warning, and a strict requirement that intrathecal chemotherapy be prepared, transported, and administered in a completely separate time window and location from intravenous vinca alkaloid administration.

Correct Answer

B — Vincristine impairs microtubule-dependent axonal transport in autonomic neurons of the enteric nervous system, disrupting the neural signals required for peristalsis and causing paralytic ileus as a dose-limiting complication

Rationale

Vincristine binds tubulin and prevents microtubule assembly, which disrupts axonal transport in peripheral and autonomic neurons. The enteric nervous system — the network of autonomic neurons governing gut motility — depends on intact microtubule-based axonal transport to sustain the neurotransmitter release and neural coordination required for peristalsis. When vincristine impairs this system, progressive constipation develops and can advance to paralytic ileus if drug is continued. This represents the autonomic component of vinca alkaloid neurotoxicity, distinct from the sensory and motor peripheral neuropathy that also occurs. Paralytic ileus is a recognized dose-limiting toxicity of vincristine that requires drug discontinuation. Vincristine does not cause direct mucosal epithelial toxicity, does not upregulate opioid receptors, and does not cause clinically significant myelosuppression at standard doses — myelosuppression is a toxicity of vinblastine and vinorelbine rather than vincristine.

Correct Answer

D — Nab-paclitaxel is formulated with albumin as the carrier instead of Cremophor EL; because the vehicle that triggered the anaphylactoid reaction is absent, taxane therapy can continue without the three-drug premedication protocol

Rationale

Conventional paclitaxel is dissolved in Cremophor EL, a polyethoxylated castor oil surfactant vehicle that directly activates complement and triggers mast cell degranulation — producing an anaphylactoid reaction that is not IgE-mediated. In patients with recurrent severe reactions despite full premedication, Cremophor EL is the problem, not paclitaxel itself. Nab-paclitaxel uses albumin nanoparticles as the delivery vehicle, entirely eliminating Cremophor EL from the formulation. Because the trigger for the anaphylactoid reaction is no longer present, nab-paclitaxel can be administered without the corticosteroid, antihistamine, and H2-blocker premedication required for conventional paclitaxel, and patients who could not tolerate conventional paclitaxel can receive taxane therapy safely. The paclitaxel molecule itself is identical in both formulations. Nab-paclitaxel does not use a modified taxane scaffold, does not employ an expanded premedication regimen, and does not rely on tolerance induction through prolonged infusion.

Correct Answer

A — Hypertonic saline, because this patient has severe symptomatic hyponatremia from vincristine-induced syndrome of inappropriate antidiuretic hormone secretion, and symptomatic hyponatremia requires active correction rather than fluid restriction alone

Rationale

Vincristine disrupts microtubule-dependent axonal transport in the hypothalamic-neurohypophyseal axis, causing antidiuretic hormone to be secreted independent of plasma osmolality — the mechanism of the syndrome of inappropriate antidiuretic hormone secretion. The result is euvolemic hyponatremia with inappropriately concentrated urine, as seen here. Management of this syndrome depends on symptom severity. Asymptomatic or mildly symptomatic hyponatremia is managed with fluid restriction. However, this patient has a serum sodium of 118 mEq per liter with acute confusion — severe symptomatic hyponatremia — which requires active correction with hypertonic saline to reduce the risk of cerebral edema and seizures. Isotonic saline would worsen hyponatremia in syndrome of inappropriate antidiuretic hormone secretion because free water is retained while sodium is excreted, and volume resuscitation is not indicated in an euvolemic patient. Fludrocortisone addresses mineralocorticoid deficiency, which is not the mechanism here. Furosemide alone without hypertonic saline is inadequate for symptomatic severe hyponatremia requiring urgent correction.

Correct Answer

C — Albumin is actively transported across tumor endothelium via albumin-binding receptors and secreted protein acidic and rich in cysteine, which is overexpressed in many solid tumors, potentially increasing paclitaxel accumulation at the tumor site

Rationale

In addition to eliminating Cremophor EL, nab-paclitaxel may offer a tumor delivery advantage through the biology of albumin transport. Many solid tumors overexpress secreted protein acidic and rich in cysteine, an albumin-binding protein that mediates transcytosis of albumin across endothelial cells. Because paclitaxel is bound to albumin nanoparticles, it may be co-transported into the tumor microenvironment via this albumin receptor-mediated pathway, potentially achieving higher intratumoral concentrations than the free drug dissolved in Cremophor EL. This proposed mechanism is one rationale for the clinical development of nab-paclitaxel beyond its safety advantage. Albumin-bound paclitaxel is not a strategy to overcome P-glycoprotein resistance — paclitaxel itself remains a P-glycoprotein substrate regardless of its carrier, and cabazitaxel is the taxane designed for P-glycoprotein evasion. Albumin nanoparticles do not cross nuclear pores, and all clinically administered paclitaxel is given intravenously, bypassing hepatic first-pass metabolism entirely.